TSS
ACAD icon

Two Sigma Securities’s Acadia Pharmaceuticals ACAD Stock Holding History

Two Sigma Securities’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-6,900
Closed -$295K – 1284
2019
Q4 		$295K Sell
6,900
-8,500
-55% -$370K ﹤0.01% 1800
2019
Q3 		$554K Buy
+15,400
New +$467K 0.01% 1150

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Two Sigma Securities's ACAD Position: Q1 2020 in Review

Two Sigma Securities sold out of Acadia Pharmaceuticals (ACAD) in Q1 2020, closing a stake of 7,269 shares — an estimated $311K sold.

Two Sigma Securities first reported a position in ACAD in Q2 2017 and held it in 4 quarters. The position peaked at $359K in Q3 2019. 246 funds tracked by Wall St. Rank hold ACAD as of Q1 2020.

  • Two Sigma Securities reported no remaining Acadia Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Two Sigma Securities sold 7,269 Acadia Pharmaceuticals shares in Q1 2020, an estimated $311K.
  • Two Sigma Securities first reported a position in Acadia Pharmaceuticals in Q2 2017 and held it in 4 quarters.
  • Two Sigma Securities's Acadia Pharmaceuticals position peaked at $359K in Q3 2019.
  • 246 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2020.

Based on Two Sigma Securities's 13F filing for Q1 2020, filed 15 May 2020.